Biotechnology company SomaLogic Inc. (Nasdaq: SLGC) nearly halved its year-over-year third quarter sales, but still managed to beat Wall Street expectations as it prepares for a $1 billion merger with California-based Standard BioTools Inc. (Nasdaq: LAB).